Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema.

Abstract

Purpose:

The purpose of this study was to evaluate the safety and preliminary efficacy of a single intravitreal injection of 3 dose levels of THR-149 in adults with center-involved diabetic macular edema (DME).

Methods:

A phase 1, open-label, multicenter 3 + 3 dose-esclation study with 3-month follow-up. The primary endpoint was the incidence of dose-limiting toxicities (DLTs) up to and including the Day 14 visit. Additional key endpoints included the incidence of (serious) adverse events ([S]AEs), mean change from baseline in best-corrected visual acuity (BCVA) and central subfield thickness (CST), and additional imaging parameters on widefield fluorescein angiography and optical coherence tomography (OCT) angiography.

Results:

Twelve subjects were treated: 3 subjects received THR-149 0.005 mg, 3 received 0.022 mg and 6 received 0.13 mg. Baseline ocular characteristics were balanced between subjects at each dose level. There were no DLTs or ocular SAEs, and all subjects completed the study. Six subjects experienced a total of 10 AEs in the study eye; 1 case of mild anterior chamber inflammation was deemed related to THR-149 and/or the injection procedure. Mean change from Baseline in BCVA was +7.5 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters on Day 14, and +6.4 ETDRS letters by Month 3. CST was variable, and mean CST change from baseline was +30.0 µm at Month 3. There were no clinically meaningful changes in imaging parameters.

Conclusions:

THR-149 was safe and well tolerated; preliminary efficacy in terms of BCVA improvement was observed.

Translational Relevance:

This work bridges the gap between basic research and clinical care by providing first in human safety and preliminary efficacy data, supporting the further investigation of THR-149 as a potential treatment for DME.

• Authors: Pravin U Dugel, Arshad M Khanani, Brian B Berger, Sunil Patel, Mitchell Fineman, Glenn J Jaffe, Petra Kozma-Wiebe, Jeffrey Heier
• Journal: Translational vision science & technology (Transl Vis Sci Technol) Vol. 10 Issue 14 Pg. 28 (12 01 2021) ISSN: 2164-2591 [Electronic] United States
• PMID: 34940810 (Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Angiogenesis Inhibitors
• Plasma Kallikrein

Topics

• Adult
• Angiogenesis Inhibitors (therapeutic use)
• Diabetes Mellitus
• Diabetic Retinopathy (drug therapy)
• Humans
• Macular Edema (drug therapy)
• Plasma Kallikrein
• Visual Acuity